Peptide News Digest

#Efpeglenatide

2 stories

Industry · View digest

Hanmi's Eppe, Korea's First Homegrown GLP-1 Obesity Drug, Reaches Patients at About Half Mounjaro's Starting Price

Prescriptions of Hanmi Pharmaceutical's once-weekly efpeglenatide, sold as Eppe, began October 29, 2026 at select Korean clinics and hospitals, after a limited first shipment on October 22, the Herald Business reported. The first four weeks cost 129,800 won, against about 270,000 won for Mounjaro's lowest dose and about 210,000 won for Wegovy, rising to 299,200 won a month at the 10 mg maintenance dose. In Hanmi's 448-patient Korean Phase 3 trial, patients lost an average of 9.75% of body weight over 40 weeks.

Regulatory · View digest

South Korea Approves Hanmi's Efpeglenatide, Its First Homegrown GLP-1 Obesity Drug, After a 448-Person Korean Phase 3 Trial

South Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's efpeglenatide, sold as Eppe, on October 7, 2026 as a once-weekly injection for chronic weight management in adults without diabetes who have a BMI of 30 or higher, or 27 or higher with a weight-related condition; it is Korea's 45th domestically developed new drug. Korean press reported average weight loss at week 40 of the 448-person Korean Phase 3 trial of 9.02% versus 0.89% on placebo (JoongAng Daily) or 9.75% (Korea Biomedical Review), with nausea in 16.6% and vomiting in 11.6%. Hanmi licensed the drug to Sanofi for diabetes in 2015, regained the rights in 2020, and has not announced a price.